NCT03899857View on ClinicalTrials.gov

Pembrolizumab for Newly Diagnosed Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Newly Diagnosed Glioblastoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be added to standard of care

Trial Locations (3)

8091

University Hospital Zurich, Zurich

Unknown

University Hospital Bern / Inselspital, Bern

University Hospital Lausanne, CHUV, Lausanne

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Zurich

OTHER

NCT03899857 - Pembrolizumab for Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter